Nycomed says that it is now marketing its Omnaris ciclesonide nasal spray for the treatment of allergic rhinitis in the United Arab Emirates (UAE). The company, a subsidiary of Takeda, says that it will launch Omnaris in other Middle East countries by the end of 2012.
According to a recent survey sponsored by Nycomed, allergic rhinitis affects over a third of UAE adults and about ten percent across the Middle East. The Allergies in the Middle East survey interviewed residents of Egypt, Iran, Lebanon, Saudi Arabia, and the UAE.
“The Allergies in the Middle East Survey highlights an unmet need for a safe, effective, fast and long-lasting allergy treatment for adults and adolescents in the Middle East where more and more people are suffering from allergic rhinitis. We are excited to be able to prescribe Omnaris to our patients in UAE as a new treatment option as approved by the authorities,” commented Dubai Hospital Director of Medical Affairs Dr. Hussain Abdul Rahman.
Read the Nycomed press release.
View the Nycomed Middle East allergy survey website.
